The findings of the two experimental studies described in the section on tumor growth and metastasis, suggest that FPR2-ERK signaling [43], TGF-β, and NR4A1 [51] are candidate targets for novel treatments of overt metastatic disease. This evidence concerns the gene TGFB1 and neoplasm.